What is the therapeutic effect of Ripotinib?

Repotrectinib is a new type of targeted drug designed to treat advanced solid tumors related to ROS1 or NTRK fusion mutations. It has high clinical application value especially in non-small cell lung cancer (NSCLC) and rare tumors. Its therapeutic effect has attracted widespread attention, mainly because of its characteristics of breaking through drug resistance, long-lasting efficacy, and strong ability to penetrate the central nervous system (CNS).

In patients targeting ROS1 fusion mutations, repotinib has shown strong therapeutic potential, especially in patients who have developed resistance after previous treatment with first-generation TKIs (such as crizotinib). It still maintains a considerable clinical response rate. Compared with other ROS1 inhibitors, reprotinib performs superiorly in its ability to target mutated resistance sites (such as G2032R), effectively prolongs progression-free survival (PFS), and brings a new option to refractory patients.

More importantly, repotinib also exhibits broad-spectrum anti-cancer effects onNTRK fusion-related tumors. Although NTRK fusion is rare in overall tumors, it involves a variety of tissue types, including salivary gland cancer, thyroid cancer, pediatric tumors, etc. As a highly selective TRK inhibitor, Ripotinib can effectively block the TRK signaling pathway, inhibit cancer cell proliferation, obtain a clear tumor shrinkage response, and even achieve complete remission in some patients.

In addition, repotinib also showed positive effects in patients with brain metastases. After its molecular structure is optimized, it has good blood-brain barrier penetration ability, can act on lesions in the central nervous system, and improve the overall control rate of patients. This has extremely high clinical value for many NSCLC patients with ROS1 fusion or NTRK fusion.

Although the efficacy is remarkable, attention should be paid to the control of adverse reactions. Common side effects include dizziness, loss of taste, fatigue, constipation, or elevated ALT, most of which are mild to moderate and can be managed through dose adjustment or symptomatic treatment.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html